Back to search results

DALY II USA/ MB-CART2019.1 for DLBCL

Abroad (travel likely)RecruitingPHASE2

Conditions

Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B Cell Lymphoma · High Grade B-cell Lymphoma (HGBCL) · Primary Mediastinal B-cell Lymphoma (PMBCL) · Transformed Lymphoma · Central Nervous System Lymphoma · Mantle Cell Lymphoma (MCL) · Richter Transformation · Transplant-ineligible 2nd Line DLBCL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Antwain Johnson) · antwaindjohnson@uabmc.edu

  • Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

    Contact: Study coordinator (Yasmin Adam) · Yasmin.Adam2@bannerhealth.com

  • Mayo Clinic, Phoenix, Arizona, United States

    Contact: Study coordinator (Allison Rosenthal, DO) · Rosenthal.Allison@mayo.edu

  • UC San Diego Health, La Jolla, California, United States

    Contact: Study coordinator (Dimitrios Tzachanis, MD) · dtzachanis@health.ucsd.edu

  • Stanford University, Stanford, California, United States

    Contact: Study coordinator (Christina Tran) · ctran13@stanford.edu

  • Colorado Blood Cancer Institute, Denver, Colorado, United States

    Contact: Study coordinator (Luke Mountjoy, MD) · luke.mountjoy@healthonecares.com

  • Yale University, New Haven, Connecticut, United States

    Contact: Study coordinator (Jialing Zhang) · jialing.zhang@yale.edu

  • Baptist Health Miami Cancer Institute, Miami, Florida, United States

    Contact: Study coordinator (Sueanna Sukie) · Sueanna.Sukie@baptisthealth.net

  • Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Amelia Langston, MD) · alangst@emory.edu

  • Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

    Contact: Study coordinator (Vamsi Kota, MD) · vkota@augusta.edu

  • Robert H Lurie Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Reem Karmali, MD) · reem.karmali@northwestern.edu

  • University of Kansas Cancer Center, Westwood, Kansas, United States

    Contact: Study coordinator (Sunil Abhyankar, MD) · sabhyankar@kumc.edu

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Nancy Hardy, MD) · nhardy1@umm.edu

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Obed Posada Villanueva) · Obed_villanueva@DFCI.HARVARD.EDU

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Maria Hollobaugh) · mholloba@med.umich.edu

  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Study coordinator (Patrick Johnston, MD) · johnston.patrick@mayo.edu

  • Washington University, St. Louis, St Louis, Missouri, United States

    Contact: Study coordinator (Amanda Cashen, MD) · acashen@wustl.edu

  • University of Nebraska Medical Center, Omaha, Nebraska, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Miguel-Angel Perales, MD) · peralesm@mskcc.org

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United States

    Contact: Study coordinator (Matthew S. McKinney, MD) · Matthew.mckinney@duke.edu

  • The Ohio State University Wexner Medical Center James Cancer, Columbus, Ohio, United States

    Contact: Study coordinator (Nathan Denlinger, DO) · nathan.denlinger@osumc.edu

  • Oregon Health and Science University Knight Cancer Institute, Portland, Oregon, United States

    Contact: Study coordinator (Richard Maziarz, MD) · maziarzr@ohsu.edu

  • Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (John Lister, MD) · john.lister@ahn.org

  • University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

  • SCRI Oncology Partners, Nashville, Tennessee, United States

    Contact: Study coordinator (Krish Patel, MD) · krish.patel@scri.com

  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Farrukh Awan, MD) · Farrukh.awan@utsouthwestern.edu

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Luhua (Michael) Wang, MD) · Miwang@mdanderson.org

  • Texas Transplant Institute, San Antonio, Texas, United States

    Contact: Study coordinator (Timothy Fenske, MD) · timothy.fenske@hcahealthcare.com

  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Jordan Gauthier, MD) · jgauthier@fredhutch.org

  • Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Jessica Eisenhauer) · jeisenhauer@mcw.edu

  • University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada

    Contact: Study coordinator (Michael Chu, MD) · michael.chu@albertahealthservices.ca

  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    Contact: Study coordinator (John Kuruvilla) · John.Kuruvilla@uhn.ca
Study leads

  • Johanna Theruvath, MD

    Study Director

    Miltenyi Biomedicine GmbH

View source on ClinicalTrials.gov(opens in a new tab)